SCHEMBL8512461

SCHEMBL8512461

CCCCCCCCCCCC(=O)N[C@H](C)C(=O)O

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 6/20 0.81
MEN1 O00255 1/20 0.69
MAPK1 P28482 1/20 0.69
KMT2A Q03164 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.67
SLC6A5 Q9Y345 1/20 0.67
NOD1 Q9Y239 3/20 0.60
DNM1 Q05193 1/20 0.56
PLA2G2C Q5R387 1/20 0.56
PLA2G10 O15496 2/20 0.55
HSP90AA1 P07900 1/20 0.53
ALDH1A1 P00352 2/20 0.53
ASAH1 Q13510 1/20 0.53
ACER2 Q5QJU3 1/20 0.53
PLA2G2A P14555 1/20 0.51
PLA2G5 P39877 1/20 0.51
ASAH2 Q9NR71 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3643202 1.00 FAAH (0.81) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL12349998 1.00 FAAH (0.81) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL17203936 1.00 FAAH (0.81) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL9652090 1.00 FAAH (0.81) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL12350003 1.00 FAAH (0.81) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL342410 1.00 FAAH (0.81) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL3994160 1.00 FAAH (0.81) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL15649884 1.00 FAAH (0.81) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL15649498 1.00 FAAH (0.81) FAAHMEN1MAPK1KMT2ASMN1; SMN2
SCHEMBL11216778 1.00 FAAH (0.81) FAAHMEN1MAPK1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170258711-A1 Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery NOVO NORDISK AS (DK) 2017-09-14 US claimed
CN-104884078-B For the fatty-acylation D amino acid of oral peptide delivery 诺和诺德股份有限公司 2017-06-20 CN claimed
WO-2015162195-A1 FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY NOVO NORDISK A/S (DK) 2015-10-29 WO claimed
US-20150265710-A1 Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery NOVO NORDISK A/S (DK) 2015-09-24 US claimed
CN-104884078-A Fatty acid acylated D-amino acids for oral peptide delivery NOVO NORDISK AS 2015-09-02 CN claimed
EP-2908846-A1 FATTY ACID ACYLATED D-AMINO ACIDS FOR ORAL PEPTIDE DELIVERY Novo Nordisk A/S (DK) 2015-08-26 EP claimed
WO-2014060447-A1 FATTY ACID ACYLATED D-AMINO ACIDS FOR ORAL PEPTIDE DELIVERY NOVO NORDISK A/S (DK) 2014-04-24 WO claimed
US-20170258711-A1 Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery NOVO NORDISK AS (DK) 2017-09-14 US disclosed
CN-104884078-B For the fatty-acylation D amino acid of oral peptide delivery 诺和诺德股份有限公司 2017-06-20 CN disclosed
WO-2015162195-A1 FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY NOVO NORDISK A/S (DK) 2015-10-29 WO disclosed
US-20150265710-A1 Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery NOVO NORDISK A/S (DK) 2015-09-24 US disclosed
CN-104884078-A Fatty acid acylated D-amino acids for oral peptide delivery NOVO NORDISK AS 2015-09-02 CN disclosed
EP-2908846-A1 FATTY ACID ACYLATED D-AMINO ACIDS FOR ORAL PEPTIDE DELIVERY Novo Nordisk A/S (DK) 2015-08-26 EP disclosed
US-20130079259-A1 OIL RELEASE WITH POLYETHYLENE OXIDE SEGMENT-CONTAINING N-LAUROYL AMINO ACID-BASED COMPOUNDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2013-03-28 US disclosed
US-20120292022-A1 COMPOSITION FOR IMPROVING OIL RECOVERY INCLUDING N-LAUROYL AMINO ACID-BASED COMPOUNDS AND MICROBES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-11-22 US disclosed
US-20120295823-A1 OIL RELEASE WITH N-LAUROYL AMINO ACID-BASED COMPOUNDS E.I DU PONT DE NEMOURS AND COMPANY (US) 2012-11-22 US disclosed
US-20120295823-A1 OIL RELEASE WITH N-LAUROYL AMINO ACID-BASED COMPOUNDS E.I DU PONT DE NEMOURS AND COMPANY (US) 2012-11-22 US disclosed
WO-2012071293-A2 COMPOSITION FOR IMPROVING OIL RECOVERY INCLUDING N-LAUROYL AMINO ACID-BASED COMPOUNDS AND MICROBES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-05-31 WO disclosed
WO-2012071291-A2 OIL RELEASE WITH N-LAUROYL AMINO ACID-BASED COMPOUNDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-05-31 WO disclosed
US-3950277-A LIPASE ENZYME AND ACTIVATORS, ALKYLNAPHTHALENE SULFONATE THE PROCTER & GAMBLE COMPANY (US) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150265710-A1 Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery SLC27A1, SLC27A2, FABP2 FAAH 83/4885MEN1 4066/4885MAPK1 4004/4885
US-20170258711-A1 Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery SLC27A1, SLC27A2, FABP2 FAAH 83/4885MEN1 4066/4885MAPK1 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.